Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.42 |
| ▸ | MEF2D | Q14814 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5993269 | 1.00 | HDAC1 (0.44) | HDAC1HDAC4MEF2DHDAC6HDAC8 | |
| SCHEMBL5991527 | 0.91 | HDAC4 (0.44) | HDAC1HDAC4MEF2DHDAC6HDAC8 | |
| SCHEMBL5991534 | 0.91 | HDAC4 (0.44) | HDAC1HDAC4MEF2DHDAC6HDAC8 | |
| SCHEMBL5992959 | 0.91 | HDAC1 (0.41) | HDAC1HDAC4HDAC6HDAC8HDAC3 | |
| SCHEMBL5992946 | 0.91 | HDAC1 (0.41) | HDAC1HDAC4HDAC6HDAC8HDAC3 | |
| SCHEMBL5995076 | 0.91 | HDAC1 (0.48) | HDAC1HDAC4MEF2DHDAC6HDAC8 | |
| SCHEMBL5995067 | 0.91 | HDAC1 (0.48) | HDAC1HDAC4MEF2DHDAC6HDAC8 | |
| SCHEMBL5994526 | 0.89 | HDAC1 (0.41) | HDAC1HDAC4MEF2DHDAC6HDAC8 | |
| SCHEMBL5994514 | 0.89 | HDAC1 (0.41) | HDAC1HDAC4MEF2DHDAC6HDAC8 | |
| SCHEMBL5994149 | 0.87 | HDAC1 (0.49) | HDAC1HDAC4HDAC6HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063760-A1 | Hydroxamic acids useful in the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063760-A1 | Hydroxamic acids useful in the treatment of hyper-proliferative disorders | MKI67, PCNA, CCNA1 | HDAC1 559/4885HDAC4 341/4885MEF2D 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.